Plasma miR-22-5p, miR-132-5p, and miR-150-3p Are Associated with Acute Myocardial Infarction

Figure 1

A flow chart of the study design strategy. The present study was conducted in the three following phases: (i) initial determination phase: we evaluated the dynamic expressions of the selected miRNAs in plasma obtained from patients with acute myocardial infarction (AMI) and control subjects (CTRL1), (ii) validation phase: we evaluated the potential diagnostic value of the selected miRNAs for discriminating AMI patients from controls, and (iii) determination phase: we evaluated the effects of heparin and medications on the plasma levels of selected miRNAs. CRTL1, control subjects presented with chest pain without coronary artery diseases (CHD); CRTL2, paroxysmal supraventricular tachycardia (PSVT) patients without medications for CHD; Medication, patients taking medications for CHD.